In silico– tag –
-
MDPI Highlights AI Drug Discovery’s Clinical Impact Deficit and Validation Crisis: AlphaFold’s Limitations and Regulatory Challenges
MDPI Switzerland Overview A review article by MDPI discusses the current state of AI in drug discovery (2022-2026), noting significant investment and accelerated early-stage discovery timelines but highlighting limited validated clinical... -
AI/Machine Learning Drives Target Identification and Precision Nanomedicine in Drug Discovery, Enhancing Candidate Selection and Pathway Analysis
Dove Medical Press USA Overview Machine learning (ML) and deep learning (DL) strategies are advancing drug discovery by enhancing target identification and precision nanomedicine. These technologies leverage virtual screening and bioacti... -
Integrating AI and Nodal Biology Accelerates Cell Response Prediction, Building Future Drug Discovery Engine
amacad.org USA Overview The integration of artificial intelligence with "nodal biology" is poised to revolutionize drug discovery by accelerating target identification through predicting human cellular responses to disease perturbations.... -
AlphaFold and AlphaFold 3 Revolutionize Protein Structure and Interaction Prediction, Significantly Accelerating Drug Discovery
IntuitionLabs / dev.to USA Overview AlphaFold and its successor, AlphaFold 3, are dramatically advancing protein structure and molecular interaction prediction, significantly compressing traditional drug discovery timelines. AlphaFold 3 ... -
AlphaFold-Derived Optimized Protein Demonstrates Significant Efficacy in Autoimmune Disease Animal Models, Accelerating AI-Driven Protein Therapeutic Design
bioRxiv Unknown Overview A bioRxiv preprint details preclinical development of a novel therapeutic protein with structure predicted and optimized using AlphaFold. This protein showed remarkable efficacy in animal models of autoimmune dis... -
Isomorphic Labs Secures $2.1 Billion to Scale AI Drug Discovery Engine, Eyes First AI-Designed Drug in Human Trials by Year-End
AI Healthcare News USA Overview Isomorphic Labs, Alphabet's AI drug discovery arm, has raised a staggering $2.1 billion to expand its "IsoDDE" AI engine. Leveraging AI in conjunction with AlphaFold 3, the company develops a platform to p... -
Veritas In Silico Advances mRNA-Targeted Small Molecule Drug Discovery with AI Platform ‘aibVIS,’ Bolstering European Collaborations
Investing.com (Fisco提供) Japan Overview Japanese biotech Veritas In Silico (VIS) is spearheading mRNA-targeted small molecule drug discovery using its proprietary AI platform, "aibVIS." This platform integrates in silico RNA structure a... -
Isomorphic Labs Secures $2.1 Billion for AI Drug Discovery, Scaling AlphaFold-Driven Platform for Diverse Modalities
Pharmaceutical Technology UK Overview Isomorphic Labs, an Alphabet-backed AI drug discovery company, has closed a monumental $2.1 billion Series B funding round to accelerate its AI-driven drug development efforts. The investment will pr...
